In the summer of 2015, a team at Boston Children’s Hospital and Harvard Medical School reported restoring rudimentary hearing in genetically deaf mice using gene therapy. Now the Boston Children’s research team reports restoring a much higher level of hearing — down to 25 decibels, the equivalent of a whisper — using an improved gene therapy vector developed at Massachusetts Eye and Ear.
While previous vectors have only been able to penetrate the cochlea’s inner hair cells, the first Nature Biotechnology study showed that a new synthetic vector, Anc80, safely transferred genes to the hard-to-reach outer hair cells when introduced into the cochlea (see images). This study’s three Harvard Medical School senior investigators were Jeffrey R. Holt PhD, of Boston Children’s Hospital; Konstantina Stankovic, MD, PhD, of Mass. Eye and Ear and Luk H. Vandenberghe, PhD, who led Anc80’s development in 2015 at Mass. Eye and Ear’s Grousbeck Gene Therapy Center.
“We have shown that Anc80 works remarkably well in terms of infecting cells of interest in the inner ear,” says Stankovic, an otologic surgeon at Mass. Eye and Ear and associate professor of otolaryngology at Harvard Medical School. “With more than 100 genes already known to cause deafness in humans, there are many patients who may eventually benefit from this technology.”
The second study, led by Gwenaëlle Géléoc, PhD, of the Department of Otolaryngology and F.M. Kirby Neurobiology Center at Boston Children’s, used Anc80 to deliver a specific corrected gene in a mouse model of Usher syndrome, the most common genetic form of deaf-blindness that also impairs balance function.
“This strategy is the most effective one we’ve tested,” Géléoc says. “Outer hair cells amplify sound, allowing inner hair cells to send a stronger signal to the brain. We now have a system that works well and rescues auditory and vestibular function to a level that’s never been achieved before.”
Ushering in gene therapy for deafness
Géléoc and colleagues at Boston Children’s Hospital studied mice with a mutation in Ush1c, the same mutation that causes Usher type 1c in humans. The mutation causes a protein called harmonin to be nonfunctional. As a result, the sensory hair cell bundles that receive sound and signal the brain deteriorate and become disorganized, leading to profound hearing loss.
When a corrected Ush1c gene was introduced into the inner ears of the mice, the inner and outer hair cells in the cochlea began to produce normal full-length harmonin. The hair cells formed normal bundles (see images) that responded to sound waves and signaled the brain, as measured by electrical recordings.
Most importantly, deaf mice treated soon after birth began to hear. Géléoc and colleagues showed this first in a “startle box,” which detects whether a mouse jumps in response to sudden loud sounds. When they next measured responses in the auditory regions of the brain, a more sensitive test, the mice responded to much quieter sounds: 19 of 25 mice heard sounds quieter than 80 decibels, and a few could heard sounds as soft as 25-30 decibels, like normal mice.
“Now, you can whisper, and they can hear you,” says Géléoc, also an assistant professor of otolaryngology at Harvard Medical School.
Margaret Kenna, MD, MPH, a specialist in genetic hearing loss at Boston Children’s who does research on Usher syndrome, is excited about the work. “Anything that could stabilize or improve native hearing at an early age would give a huge boost to a child’s ability to learn and use spoken language,” she says. “Cochlear implants are great, but your own hearing is better in terms of range of frequencies, nuance for hearing voices, music and background noise, and figuring out which direction a sound is coming from. In addition, the improvement in balance could translate to better and safer mobility for Usher Syndrome patients.”
Restoring balance and potentially vision
Since patients (and mice) with Usher 1c also have balance problems caused by hair-cell damage in the vestibular organs, the researchers also tested whether gene therapy restored balance. It did, eliminating the erratic movements of mice with vestibular dysfunction (see images) and, in another test, enabled the mice to stay on a rotating rod for longer periods without falling off.
Further work is needed before the technology can be brought to patients. One caveat is that the mice were treated right after birth; hearing and balance were not restored when gene therapy was delayed 10-12 days. The researchers will do further studies to determine the reasons for this. However, when treated early, the effects persisted for at least six months, with only a slight decline between 6 weeks and 3 months. The researchers also hope to test gene therapy in larger animals, and plan to develop novel therapies for other forms of genetic hearing loss.
Usher syndrome also causes blindness by causing the light-sensing cells in the retina to gradually deteriorate. Although these studies did not test for vision restoration, gene therapy in the eye is already starting to be done for other disorders.
“We already know the vector works in the retina,” says Géléoc, “and because deterioration is slower in the retina, there is a longer window for treatment.”
“Progress in gene therapy for blindness is much further along than for hearing, and I believe our studies take an important step toward unlocking a future of hearing gene therapy,” says Vandenberghe, also an assistant professor of ophthalmology at Harvard Medical School. “In the case of Usher syndrome, combining both approaches to ultimately treat both the blinding and hearing aspects of disease is very compelling, and something we hope to work toward.”
“This is a landmark study,” says Holt, director of otolaryngology research at Boston Children’s Hospital, who was also a co-author on the second paper. “Here we show, for the first time, that by delivering the correct gene sequence to a large number of sensory cells in the ear, we can restore both hearing and balance to near-normal levels.”
Receive an email update when we add a new GENE THERAPY article.
The Latest on: Hearing gene therapy
via Google News
The Latest on: Hearing gene therapy
- Sensorion to Attend and Present at LSX World Congress 2020on February 2, 2020 at 9:30 pm
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL ... of 2019 two preclinical gene therapy programs aiming at ...
- Boston area startups making slow progress in fight against hearing losson February 2, 2020 at 2:55 pm
When a small cluster of biotechs working on drugs for hearing loss cropped up in the Boston area several years ago, it raised the hopes of legions of mostly older people who rely on hearing aids or ...
- Adeno-associated virus vector enables safe and efficient Cas9 activation in neonatal and adult Cas9 knockin murine cochleaeon January 31, 2020 at 6:39 am
Mol Ther. 2005;12:725–33. Akil O, Seal RP, Burke K, Wang C, Alemi A, During M, et al. Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy. Neuron. 2012;75:283–93.
- Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focuson January 29, 2020 at 7:05 am
That drug is intended to protect cells involved in hearing from the toxic effects of chemotherapy. It’s currently in Phase 1b testing. Another pipeline candidate, DB-OTO, is being developed to treat ...
- Best Life: Beethoven mice prevent deafness - medicine’s next big thing?on January 29, 2020 at 4:48 am
Researchers identified that a hearing gene called TMC one ... It’s important to note that Holt holds patents on TMC one gene therapy.
- Decibel Therapeutics Announces Strategic Research Focus on Regenerative Medicine for the Inner Earon January 29, 2020 at 4:26 am
“We see an exciting opportunity to leverage this platform to address a broad range of hearing and balance disorders that severely compromise quality of life for hundreds of millions of people around ...
- The FDA unveils a new regulatory framework to speed along gene therapies, rewarding the leading playerson January 28, 2020 at 11:12 pm
Otonomy was founded in 2008 and is dedicated to finding new drug treatments for the hugely underserved community living with balance and hearing ... of its first three gene therapy programs.
- Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Programon January 28, 2020 at 3:30 am
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
- Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meetingon January 24, 2020 at 4:07 pm
Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston ...
via Bing News